Did You Know...
...During the Civil War, the Confederacy established its own Patent Office which issued 266 patents, a third of which concerned implements of war.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8329875 | Antibodies to an epitope of AGR2, assays and hybridomas Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigatio... | 12/11/2012 |
| 8106170 | Compositions against SARS-coronavirus and uses thereof The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition... | 01/31/2012 |
| 7947812 | Neoplasm specific antibodies and uses thereof The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms. ... | 05/24/2011 |
| 7786275 | Identification of a unique core domain of Par-4 sufficient for selective apoptosis induction in cancer cells The present invention relates to Par-4 mutants which cause apoptosis in cancer cells which are sensitive to Par-4 and also induce apoptosis in cancer cells which are resistant to Par-4. The present invention also relates to methods of using the Par-4 mutant to treat... | 08/31/2010 |
| 7696330 | Binding molecules against SARS-coronavirus and uses thereof The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molec... | 04/13/2010 |
| 7608696 | IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of tr... | 10/27/2009 |
| 7531643 | Monoclonal antibody inducing apoptosis The monoclonal antibodies of this invention are antibodies that specifically recognize human Integrin Associated Protein, and the antigens that induce apoptosis of nucleated blood cells having human Integrin Associated Protein. Accordingly, they are useful as antibo... | 05/12/2009 |
| 7521543 | A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing ... | 04/21/2009 |
| 7517967 | Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also... | 04/14/2009 |
| 7476724 | Humanized anti-cmet antibodies The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. ... | 01/13/2009 |
| 7459539 | Antibody that binds zinc transporter protein 108P5H8 A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 108P5H8 provides a ... | 12/02/2008 |
| 7435804 | Method for obtaining single chain antibodies to human interferon α2b A bacterial high-expression system which is applicable for simultaneous screening of large numbers of recombinant clones from combinatorial antibody libraries is disclosed. The method pertains to screening of single chain antibodies from libraries expressed in the p... | 10/14/2008 |
| 7435803 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 10/14/2008 |
| 7431926 | Tumor supressor gene p33ING2 The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods ... | 10/07/2008 |
| RE40535 | Anti-KC4 humanized monoclonal antibody and cells that express the antibody An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with ... | 10/07/2008 |
| 7429382 | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provi... | 09/30/2008 |
| 7425623 | Antibody with specificity for colon cancer A binding structure which binds in, and/or to the surface of, tumour cells; a target structure displayed and/or expressed in, or on the surface of, tumour cells; a binding structure that recognises and blocks said target structure; a substance that binds to or block... | 09/16/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7420039 | Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production o... | 09/02/2008 |
| 7419794 | Antibodies specific for CYP1B1 Antibodies that can specially bind to cytochrome P450 CYP1B1 and methods of making them are disclosed, in particular antibodies that bind to amino acid sequence VNQWSVNHDPVKWPN or PExFDPARFLDKDGy, where x is D or N and y is L or F, or an antigenic fragment thereof. ... | 09/02/2008 |
| 7413737 | Anti-hydroxylase antibodies and uses thereof Antibodies, or antigen-binding portions thereof, to aspartyl (asparaginyl) β-hydroxylase are provided. The anti-aspartyl (asparaginyl) β-hydroxylase antibodies, or antigen-binding portions thereof, can modulate activity of aspartyl (asparaginyl) β-hydroxylase. | 08/19/2008 |
| 7411046 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 08/12/2008 |
| 7407656 | PSCA: prostate stem cell antigen and uses thereof The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and an... | 08/05/2008 |
| 7399835 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 07/15/2008 |
| 7396914 | SARS nucleic acids, proteins, antibodies, and uses thereof Codon-optimized nucleic acids, polypeptides, and antibodies are described herein. ... | 07/08/2008 |
| 7393531 | Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 07/01/2008 |
| 7393933 | Hepatitis B monoclonal antibodies A monoclonal antibody that is capable of binding specifically to wild type HBsAg and to at least two mutant forms of HBsAg may be used in an improved immunoassay for the detection of both escape mutants and wild type HBsAg and may be used for passive immunisation ag... | 07/01/2008 |
| 7378094 | Therapeutic uses of complement receptor 2 The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific f... | 05/27/2008 |
| 7378091 | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity ... | 05/27/2008 |
| 7371827 | Antibodies against the PRO1126 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 05/13/2008 |
| 7368110 | Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use Mesothelin ins a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediat... | 05/06/2008 |
| 7361340 | Antibody against tumor specific antigen as target The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, th... | 04/22/2008 |
| 7361341 | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid m... | 04/22/2008 |
| 7361342 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 04/22/2008 |
| 7355013 | PRO6017 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 04/08/2008 |
| 7354762 | Method for producing CE7-specific redirected immune cells Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 04/08/2008 |
| 7354587 | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tu... | 04/08/2008 |
| 7348414 | Antibodies against the PRO1154 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 03/25/2008 |
| 7348413 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 03/25/2008 |
| 7348003 | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to... | 03/25/2008 |
